Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).

MLA

Kobayashi, Kazufumi, et al. “Ramucirumab for Advanced Hepatocellular Carcinoma in the Current Real World: A Japanese Single-Arm Study Post-REACH-2 (The R-Evolution Study).” Investigational New Drugs, vol. 42, no. 4, Aug. 2024, pp. 394–404. EBSCOhost, https://doi.org/10.1007/s10637-024-01441-3.

APA

Kobayashi, K., Ogasawara, S., Itobayashi, E., Okubo, T., Itokawa, N., Nakamura, K., Moriguchi, M., Watanabe, S., Ikeda, M., Kuroda, H., Kawaoka, T., Hiraoka, A., Yasui, Y., Kuzuya, T., Sato, R., Kanzaki, H., Koroki, K., Inoue, M., Nakamura, M., & Kiyono, S. (2024). Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Investigational New Drugs, 42(4), 394–404. https://doi.org/10.1007/s10637-024-01441-3

Chicago

Kobayashi, Kazufumi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa, Kazuyoshi Nakamura, Michihisa Moriguchi, et al. 2024. “Ramucirumab for Advanced Hepatocellular Carcinoma in the Current Real World: A Japanese Single-Arm Study Post-REACH-2 (The R-Evolution Study).” Investigational New Drugs 42 (4): 394–404. doi:10.1007/s10637-024-01441-3.